alendronate has been researched along with Pregnancy in 22 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Taking into account their medical past, two drugs were possibly involved: either oral alendronate that their mother had received before pregnancy for misdiagnosed osteoporosis or antireflux medications, or both." | 7.83 | Neonatal transient hypophosphatemic hypercalciuric rickets in dizygous twins: A role for maternal alendronate therapy before pregnancy or antireflux medications? ( Bacchetta, J; Claris, O; Cochat, P; Fouque-Aubert, A; Gerin, M; Jambon, G; Raybaud, C, 2016) |
| " Taking into account their medical past, two drugs were possibly involved: either oral alendronate that their mother had received before pregnancy for misdiagnosed osteoporosis or antireflux medications, or both." | 3.83 | Neonatal transient hypophosphatemic hypercalciuric rickets in dizygous twins: A role for maternal alendronate therapy before pregnancy or antireflux medications? ( Bacchetta, J; Claris, O; Cochat, P; Fouque-Aubert, A; Gerin, M; Jambon, G; Raybaud, C, 2016) |
| "Alendronate sodium is an aminobiphosphonate, an analog of inorganic pyrophosphate, indicated for the treatment of osteoporosis in post-menopausal women." | 3.72 | Pharmacovigilance study of alendronate in England. ( Biswas, PN; Shakir, SA; Wilton, LV, 2003) |
| "Osteoporosis is defined by loss of bone mass and deteriorated bone microarchitecture." | 1.72 | Pharmacological and Non-Pharmacological Agents versus Bovine Colostrum Supplementation for the Management of Bone Health Using an Osteoporosis-Induced Rat Model. ( Amorim, T; Bastos, AR; Canadas, RF; Carrillo, AE; Correlo, VM; Fernandes, EM; Freitas, L; Gkiata, P; Koutedakis, Y; Kydonaki, EK; Marques, F; Ntina, G; Oliveira, JM; Pinto, R; Reguengo, H; Reis, RL; Simón, CR; Vliora, M, 2022) |
| " We also show that temporary administration of the bisphosphonate alendronate, either just before or just after pregnancy, to female mice was protective against bone loss due to pregnancy or lactation and had no adverse effects on offspring, such as growth retardation." | 1.62 | Transient alendronate administration to pregnant or lactating mothers prevents bone loss in mice without adverse effects on offspring. ( Ito, E; Kimura, A; Kobayashi, T; Matsumoto, H; Matsumoto, M; Matsumoto, T; Miyamoto, K; Miyamoto, T; Nakamura, M; Sato, K; Sato, Y; Soma, T, 2021) |
| "Many women now survive breast cancer, but find themselves at increased risk of menopausal complications." | 1.31 | Managing menopause after breast cancer: balancing risks and benefits. ( Moore, HC, 2001) |
| "14C-alendronate was shown to pass through the rat placenta and accumulate in the fetuses, most probably in their bones." | 1.30 | Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. ( Breuer, E; Golomb, G; Ornoy, A; Patlas, N; Pinto, T; Yaffe, P, 1999) |
| "Alendronate is a bisphosphonate which inhibits bone resorption." | 1.29 | Effects of the bisphosphonate, alendronate, on parturition in the rat. ( Manson, JM; Minsker, DH; Peter, CP, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 6 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Kydonaki, EK | 1 |
| Freitas, L | 1 |
| Reguengo, H | 1 |
| Simón, CR | 1 |
| Bastos, AR | 1 |
| Fernandes, EM | 1 |
| Canadas, RF | 1 |
| Oliveira, JM | 1 |
| Correlo, VM | 1 |
| Reis, RL | 1 |
| Vliora, M | 1 |
| Gkiata, P | 1 |
| Koutedakis, Y | 1 |
| Ntina, G | 1 |
| Pinto, R | 1 |
| Carrillo, AE | 1 |
| Marques, F | 1 |
| Amorim, T | 1 |
| Eswarakumar, A | 1 |
| Robinson, C | 1 |
| Carpenter, TO | 1 |
| Bacchetta, J | 2 |
| Garnier, C | 1 |
| Jia, P | 1 |
| Wang, R | 1 |
| Yuan, J | 1 |
| Chen, H | 1 |
| Bao, L | 1 |
| Feng, F | 1 |
| Tang, H | 1 |
| Sifrig, B | 1 |
| Grozenski, A | 1 |
| Brown, L | 1 |
| Coleman, J | 1 |
| Ito, E | 1 |
| Sato, Y | 1 |
| Kobayashi, T | 1 |
| Soma, T | 1 |
| Matsumoto, T | 1 |
| Kimura, A | 1 |
| Miyamoto, K | 1 |
| Matsumoto, H | 1 |
| Matsumoto, M | 1 |
| Nakamura, M | 1 |
| Sato, K | 1 |
| Miyamoto, T | 1 |
| Gerin, M | 1 |
| Jambon, G | 1 |
| Fouque-Aubert, A | 1 |
| Raybaud, C | 1 |
| Cochat, P | 1 |
| Claris, O | 1 |
| Ofluoglu, O | 1 |
| Ofluoglu, D | 1 |
| McKenna, M | 1 |
| Mansfield, JC | 1 |
| Rozenbaum, M | 1 |
| Boulman, N | 1 |
| Rimar, D | 1 |
| Kaly, L | 1 |
| Rosner, I | 1 |
| Slobodin, G | 1 |
| Dytfeld, J | 1 |
| Horst-Sikorska, W | 1 |
| Biswas, PN | 1 |
| Wilton, LV | 1 |
| Shakir, SA | 1 |
| Rutgers-Verhage, AR | 1 |
| deVries, TW | 1 |
| Torringa, MJ | 1 |
| Sarikaya, S | 1 |
| Ozdolap, S | 1 |
| Açikgöz, G | 1 |
| Erdem, CZ | 1 |
| Kabi, F | 1 |
| Mkinsi, O | 1 |
| Zrigui, J | 1 |
| Ornoy, A | 2 |
| Wajnberg, R | 1 |
| Diav-Citrin, O | 1 |
| Athimulam, S | 1 |
| Chan, P | 1 |
| Baker, M | 1 |
| Nauta, M | 1 |
| Yoong, W | 1 |
| Minsker, DH | 1 |
| Manson, JM | 1 |
| Peter, CP | 1 |
| van Beek, ER | 1 |
| Löwik, CW | 1 |
| Ebetino, FH | 1 |
| Papapoulos, SE | 1 |
| Patlas, N | 1 |
| Golomb, G | 1 |
| Yaffe, P | 1 |
| Pinto, T | 1 |
| Breuer, E | 1 |
| Moore, HC | 1 |
| Harsch, IA | 1 |
| Hübner, RH | 1 |
| Hahn, EG | 1 |
| Hensen, J | 1 |
1 review available for alendronate and Pregnancy
| Article | Year |
|---|---|
A case of pregnancy and lactation-associated osteoporosis and a review of the literature.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium Carbonate; Drug Therapy, | 2020 |
21 other studies available for alendronate and Pregnancy
| Article | Year |
|---|---|
Pharmacological and Non-Pharmacological Agents versus Bovine Colostrum Supplementation for the Management of Bone Health Using an Osteoporosis-Induced Rat Model.
Topics: Alendronate; Animals; Body Weight; Bone Density; Cattle; Colostrum; Dietary Supplements; Female; Hum | 2022 |
Response to report of rickets in twins occurring after maternal bisphosphonate exposure.
Topics: Alendronate; Familial Hypophosphatemic Rickets; Female; Humans; Hypercalciuria; Infant, Newborn; Pre | 2020 |
Response to: Neonatal transient hypophosphatemic hypercalciuric rickets in dizygous twins.
Topics: Alendronate; Familial Hypophosphatemic Rickets; Female; Humans; Hypercalciuria; Infant, Newborn; Pre | 2020 |
An Uncommon Cause of Debilitating Hip Pain in Pregnancy.
Topics: Adult; Alendronate; Arthralgia; Bed Rest; Bone Density Conservation Agents; Crutches; Female; Hip; H | 2021 |
Transient alendronate administration to pregnant or lactating mothers prevents bone loss in mice without adverse effects on offspring.
Topics: Alendronate; Animals; Bone Density; Female; Humans; Lactation; Mice; Mothers; Pharmaceutical Prepara | 2021 |
Neonatal transient hypophosphatemic hypercalciuric rickets in dizygous twins: A role for maternal alendronate therapy before pregnancy or antireflux medications?
Topics: Alendronate; Anti-Ulcer Agents; Bone Density Conservation Agents; Esomeprazole; Female; Humans; Hype | 2016 |
A case report: pregnancy-induced severe osteoporosis with eight vertebral fractures.
Topics: Adult; Alendronate; Back Pain; Bone Density; Bone Density Conservation Agents; Female; Fractures, Sp | 2008 |
Safety of bisphosphonates in women of child bearing age.
Topics: Alendronate; Bone Density Conservation Agents; Colitis, Ulcerative; Diphosphonates; Female; Humans; | 2009 |
Uncommon transient osteoporosis of pregnancy at multiple sites associated with cytomegalovirus infection: is there a link?
Topics: Absorptiometry, Photon; Adult; Alendronate; Ankle Joint; Bone Density Conservation Agents; Cytomegal | 2011 |
Pregnancy associated osteoporosis--a case report.
Topics: Adult; Alendronate; Back Pain; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Fem | 2012 |
Pharmacovigilance study of alendronate in England.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Angioedema; Cohort Studies; Erythema Multiforme; Family | 2003 |
No effects of bisphosphonates on the human fetus.
Topics: Alendronate; Female; Humans; Maternal Age; Maternal Exposure; Middle Aged; Osteoporosis; Pregnancy; | 2003 |
Pregnancy-associated osteoporosis with vertebral fractures and scoliosis.
Topics: Absorptiometry, Photon; Adult; Alendronate; Back Pain; Bone Density; Calcium Carbonate; Exercise The | 2004 |
[Pregnancy-associated osteoporosis. A new case].
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Follow-Up Studies; Fract | 2006 |
The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment.
Topics: Adult; Alendronate; Arthritis, Psoriatic; Arthritis, Rheumatoid; Asthma; Behcet Syndrome; Berylliosi | 2006 |
The effect of pregnancy on pre-existing osteopenia: a case report.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female | 2007 |
Effects of the bisphosphonate, alendronate, on parturition in the rat.
Topics: Alendronate; Animals; Calcium; Diphosphonates; Female; Fertility; Hypocalcemia; Labor, Obstetric; Ma | 1993 |
Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships.
Topics: Alendronate; Animals; Bone and Bones; Bone Resorption; Calcification, Physiologic; Calcium; Culture | 1998 |
Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats.
Topics: Alendronate; Animals; Bone and Bones; Calcification, Physiologic; Diphosphonates; Female; Fetus; Pre | 1999 |
Managing menopause after breast cancer: balancing risks and benefits.
Topics: Adult; Alendronate; Antidepressive Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Calcit | 2001 |
[Osteoporosis and multiple pregnancy--a case report with positive outcome].
Topics: Adult; Alendronate; Bone Density; Calcium Channel Agonists; Calcium, Dietary; Cholecalciferol; Contr | 2001 |